Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4485364 | 0.98 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| Water SCHEMBL27520041 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| SCHEMBL28862327 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL221473 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL20817034 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28158071 | 0.77 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL6952064 | 0.76 | NAAA (0.41) | — | |
| SCHEMBL6949604 | 0.76 | — | — | |
| SCHEMBL28003206 | 0.76 | — | — | |
| SCHEMBL9499335 | 0.75 | CYP1A2 (0.38) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10443026-B2 | Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2019-10-15 | — | — | US | disclosed |
| CN-110049983-A | Medical compounds | 细胞中心有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-110036002-A | Medical compounds | 细胞中心有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20190194590-A1 | POLYGONAL SCAFFOLD AND MANUFACTURING METHOD THEREOF, AND PROTEIN MODULATOR AND MANUFACTURING METHOD THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2019-06-27 | — | — | US | disclosed |
| CN-105163733-A | Furanone compounds as kinase inhibitors | ETERNITY BIOSCIENCE INC | 2015-12-16 | — | — | CN | disclosed |
| EP-0724651-B1 | SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6960560-B2 | Iron chelator delivery system | GWATHMEY, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050048070-A1 | Cancer-associated epitope | SCRIPPS RESEARCH INSTITUTE, THE | 2005-03-03 | — | — | US | disclosed |
| EP-1461001-A2 | CANCER-ASSOCIATED EPITOPE | The Scripps Research Institute (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003057168-A2 | CANCER-ASSOCIATED EPITOPE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6395275-B1 | REDUCES TITER BY 50% IN AN IN VITRO ASSAY; DIAGNOSIS AND IMMUNOTHERAPY | THE SCRIPPS RESEARCH INSTITUTE | 2002-05-28 | — | — | US | disclosed |
| US-20010033860-A1 | Iron chelator delivery system | GWATHMEY, INC. | 2001-10-25 | — | — | US | disclosed |
| US-6261558-B1 | IMMUNOTHERAPY; DIAGNOSIS | THE SCRIPPS RESEARCH INSTITUTE | 2001-07-17 | — | — | US | disclosed |
| WO-2001049266-A2 | IRON CHELATOR DELIVERY SYSTEM | GWATHEMY JUDITH K (US) | 2001-07-12 | — | — | WO | disclosed |
| US-5962634-A | PEPTIDE OF 6 TO 25 AMINO ACIDS WHICH MODULATES IMMUNOGLOBULIN E BINDING TO FC EPSILON RECEPTOR 1; FOR TREATMENT AND PROPHYLAXIS OF GRAFT VS HOST DISEASE, ALLERGIC RHINITIS, FOOD ALLERGIES, ATROPIC DERMATITIS, AND ALLERGIC ASTHMA | THOMAS JEFFERSON UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0724651-A4 | SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | SCRIPPS RESEARCH INST (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0724651-A1 | SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996001643-A1 | IgE ANTAGONISTS | THOMAS JEFFERSON UNIVERSITY (US) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995011317-A1 | SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-04-27 | — | — | WO | disclosed |
| US-4043818-A | Process for hardening photographic layers with carbodiimide compounds containing sulphobetaine groups | AGFA-GEVAERT, A.G. (DT) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194590-A1 | POLYGONAL SCAFFOLD AND MANUFACTURING METHOD THEREOF, AND PROTEIN MODULATOR AND MANUFACTURING METHOD THEREOF | PPIA, PPIH, FKBP1A | CYP1A2 3805/4885CYP2D6 4137/4885 |
| US-10443026-B2 | Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof | PPIA, PPIH, FKBP1A | CYP1A2 4091/4885CYP2D6 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.